The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to develop ...
The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises options to develop
New late-breaking data presentations underscore Jazz's significant progress in advancing holistic understanding of narcolepsy and idiopathic hypersomnia, including novel real-world evidence of meaningful...
Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?
Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ)
For U.S. media and investors only
Twenty-one abstracts, including 11 late-breaking abstracts, underscore Jazz's unwavering commitment to advancing the treatment of narcolepsy and idiopathic hypersomnia
